Tango Therapeutics TNGX Business Segments
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| Research And Development Expense by Business | ||||||
| Discovery Direct Program Expenses-RD | $7.36M-27.6% | $10.17M-24.2% | $13.41M-28.7% | $18.8M-20.4% | $23.61M-3.4% | |
| Facilities And Other Related Expenses-RD | $19.34M-5.5% | $20.46M+5.8% | $19.34M-0.8% | $19.49M+0.1% | $19.47M+3.1% | |
| Personnel-Related Expenses-RD | $50.56M-1.8% | $51.47M-1.4% | $52.21M-0.1% | $52.24M-0.5% | $52.51M+2.0% | |
| TNG260Direct Program Expenses-RD | $6.56M+4.4% | $6.28M-5.4% | $6.64M-4.1% | $6.92M-22.0% | $8.88M-5.4% | |
| TNG456Direct Program Expenses-RD | $7.3M+11.3% | $6.56M-31.0% | $9.5M+26.6% | $7.5M+28.1% | $5.86M+29.2% | |
| TNG908Direct Program Expenses-RD | $3.9M-22.5% | $5.03M-28.1% | $6.99M-22.5% | $9.02M-18.3% | $11.04M-18.7% | |
| TNG961Direct Program Expenses-RD | $3.86M-31.9% | $5.68M+16.7% | $4.86M+28.2% | $3.79M+70.8% | $2.22M— | |
| Vopimetostat Direct Program Expenses-RD | $30.39M+14.6% | $26.52M+25.7% | $21.11M+16.3% | $18.16M— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How does Tango Therapeutics break its business down?
- Tango Therapeutics (TNGX) reports research and development expense by business across 8 parts — Discovery Direct Program Expenses-RD, Facilities And Other Related Expenses-RD, Personnel-Related Expenses-RD, TNG260Direct Program Expenses-RD and TNG456Direct Program Expenses-RD. Each is extracted from the segment footnotes and tracked over time.
- Where does Tango Therapeutics's segment data come from?
- Segment breakdowns are pulled from the segment footnotes in Tango Therapeutics's SEC filings (the XBRL dimensional tags), so every line ties back to a reported figure. Switch between quarterly, annual, and TTM, or open any segment for its full history.